Biomerica Inc (BMRA) Q3 2026 Earnings Report

Biomerica, a small-cap diagnostic and therapeutic products company, reported QQ3 2026 revenue of $0.987 million and a negative gross profit of $0.044 million, contributing to a net loss of $1.312 million ($0.44 per share) for the quarter. On a YoY basis, revenue declined approximately 39.7% and gross profit deteriorated meaningfully, with EBITDA at a loss of $1.298 million and an EBITDA margin of −1.32x. Management commentary in the earnings materials points to ongoing investments in product development and pipeline initiatives (notably InFoods IBS therapy and Helicobacter pylori diagnostics), but near-term profitability remains elusive as the company operates with limited scale and elevated SG&A and R&D expenses relative to quarterly revenue. On the balance sheet, Biomerica shows a modest liquidity cushion with cash and equivalents of about $1.34 million and a net cash position of roughly $1.14 million, while total assets stood at $4.88 million and stockholders’ equity at $3.32 million. The company’s-year-to-date trajectory suggests a transition phase focused on pipeline advancement rather than immediate bottom-line expansion, elevating execution risk but offering potential upside if pipeline milestones and new commercial wins materialize.